DE69931029D1 - Optimierte antisense oligonukleotide komplementär zu dna-methyltransferase sequenzen - Google Patents

Optimierte antisense oligonukleotide komplementär zu dna-methyltransferase sequenzen

Info

Publication number
DE69931029D1
DE69931029D1 DE69931029T DE69931029T DE69931029D1 DE 69931029 D1 DE69931029 D1 DE 69931029D1 DE 69931029 T DE69931029 T DE 69931029T DE 69931029 T DE69931029 T DE 69931029T DE 69931029 D1 DE69931029 D1 DE 69931029D1
Authority
DE
Germany
Prior art keywords
antisense oligonucleotides
dna methyltransferase
oligonucleotides complementary
optimized antisense
methyltransferase sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69931029T
Other languages
English (en)
Other versions
DE69931029T2 (de
Inventor
A Macleod
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Methylgene Inc
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of DE69931029D1 publication Critical patent/DE69931029D1/de
Application granted granted Critical
Publication of DE69931029T2 publication Critical patent/DE69931029T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
DE69931029T 1998-02-03 1999-02-03 Optimierte antisense oligonukleotide komplementär zu dna-methyltransferase sequenzen Expired - Fee Related DE69931029T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18034 1998-02-03
US09/018,034 US6066625A (en) 1998-02-03 1998-02-03 Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences
PCT/CA1999/000092 WO1999040186A1 (en) 1998-02-03 1999-02-03 Optimized antisense oligonucleotides complementary to dna methyltransferase sequences

Publications (2)

Publication Number Publication Date
DE69931029D1 true DE69931029D1 (de) 2006-06-01
DE69931029T2 DE69931029T2 (de) 2006-11-23

Family

ID=21785911

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69931029T Expired - Fee Related DE69931029T2 (de) 1998-02-03 1999-02-03 Optimierte antisense oligonukleotide komplementär zu dna-methyltransferase sequenzen

Country Status (11)

Country Link
US (2) US6066625A (de)
EP (1) EP1053313B1 (de)
JP (1) JP3766592B2 (de)
AT (1) ATE324440T1 (de)
AU (1) AU758835B2 (de)
CA (1) CA2319086A1 (de)
DE (1) DE69931029T2 (de)
DK (1) DK1053313T3 (de)
ES (1) ES2263267T3 (de)
PT (1) PT1053313E (de)
WO (1) WO1999040186A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032610A1 (en) 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
US7026155B2 (en) * 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
AU2001259370A1 (en) * 2000-05-09 2001-11-20 Isis Pharmaceuticals, Inc. Methods of obtaining active antisense compounds
GB2392911A (en) * 2001-05-11 2004-03-17 Methylgene Inc Inhibitors of dna methyltransferase isoforms
EP2505591A1 (de) 2005-02-11 2012-10-03 Memorial Sloan-Kettering Cancer Center Verfahren und Zusammensetzungen zur Detektion eines arzneimittelresistenten EGFR-Mutanten
WO2006107751A2 (en) * 2005-04-01 2006-10-12 Methylgene, Inc. Combined therapy utilizing reduction of dna methyltansferase expression and/or activity and interferon
MX2007014616A (es) 2005-05-20 2009-08-12 Methylgene Inc Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
AU2006275479B2 (en) * 2005-08-01 2012-11-29 Nupotential, Inc. Production of reprogrammed cells with restored potential
EP4332227A1 (de) 2005-08-23 2024-03-06 The Trustees of the University of Pennsylvania Rna-haltige modifizierte nukleoside und verfahren zur verwendung davon
US20080064718A1 (en) * 2006-03-22 2008-03-13 Saavedra Oscar M Inhibitors of protein tyrosine kinase activity
US20080004273A1 (en) * 2006-05-30 2008-01-03 Stephane Raeppel Inhibitors of protein tyrosine kinase activity
US20080255155A1 (en) * 2006-10-18 2008-10-16 Stephane Raeppel Kinase inhibitors and uses thereof
WO2009089598A2 (en) * 2008-01-18 2009-07-23 Katholieke Universiteit Leuven Msmb-gene methylation based diagnosis, staging and prognosis of prostate cancer
WO2010045095A1 (en) 2008-10-14 2010-04-22 Ning Xi Compounds and methods of use
GB201001088D0 (en) 2010-01-23 2010-03-10 Trillion Genomics Ltd Detection
RU2568258C2 (ru) 2011-02-28 2015-11-20 Саншайн Лейк Фарма Ко., Лтд Замещенные соединения хинолина и способы их использования
GB201206209D0 (en) 2012-04-06 2012-05-23 Univ Leuven Kath Marker gene based diagnosis, staging and prognosis of prostate caner
WO2014022116A2 (en) 2012-07-28 2014-02-06 Calitor Sciences, Llc Substituted pyrazolone compounds and methods of use
TWI574962B (zh) 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
AU2014219256B2 (en) 2013-02-21 2017-02-16 Sunshine Lake Pharma Co., Ltd. Heteroaromatic compounds as PI3 kinase modulators
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
EP3124609A1 (de) 2015-07-29 2017-02-01 IFOM Fondazione Istituto Firc di Oncologia Molecolare Therapeutische oligonukleotide
EP3650546A1 (de) 2015-07-29 2020-05-13 IFOM Fondazione Istituto Firc di Oncologia Molecolare Therapeutische oligonukleotide
WO2017067447A1 (en) 2015-10-19 2017-04-27 Sunshine Lake Pharma Co., Ltd. A salt of egfr inhibitor, crystalline form and uses thereof
WO2018185341A1 (en) 2017-04-07 2018-10-11 Ospedale San Raffaele S.R.L. Regulator of bmp-smad signaling and uses thereof
WO2018194342A2 (en) * 2017-04-17 2018-10-25 Seegene, Inc. . Methods for preparing optimal combination of oligonucleotides
WO2023081927A2 (en) * 2021-11-08 2023-05-11 The General Hospital Corporation Treating chemoresistant forms of leukemia and other cancers that overexpress rna binding protein fxr1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030557A (en) * 1987-11-24 1991-07-09 Ml Technology Venture Means and method for enhancing nucleic acid hybridization
US5652355A (en) * 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides

Also Published As

Publication number Publication date
AU758835B2 (en) 2003-04-03
EP1053313A1 (de) 2000-11-22
ES2263267T3 (es) 2006-12-01
JP3766592B2 (ja) 2006-04-12
ATE324440T1 (de) 2006-05-15
DK1053313T3 (da) 2006-08-28
US6506735B1 (en) 2003-01-14
CA2319086A1 (en) 1999-08-12
PT1053313E (pt) 2006-06-30
US6066625A (en) 2000-05-23
AU2405999A (en) 1999-08-23
EP1053313B1 (de) 2006-04-26
JP2002502602A (ja) 2002-01-29
WO1999040186A1 (en) 1999-08-12
DE69931029T2 (de) 2006-11-23

Similar Documents

Publication Publication Date Title
ATE324440T1 (de) Optimierte antisense oligonukleotide komplementär zu dna-methyltransferase sequenzen
EP1100809A4 (de) 2'-modifizierte oligonucleotide mit rns wirkung, die konformell eingeschränkt sind
DK0691980T3 (da) 7-deazapurinmodifiderende oligonukleotider
WO1999010486A3 (en) Mdm2-specific antisense oligonucleotides
PT731835E (pt) Oligonucleotidos anti-sentido possuindo actividade inibidora de tumorigenicidade
DE69838449D1 (de) Aminooxy-modifizierte oligonukleotide
DE60024660D1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
IL113804A0 (en) Antisense oligonucleotide modulation of raf gene expression
DE69433626D1 (de) N-2 substituierte purine
EP0788307A4 (de) Oligonukleotidmodulation von multidrogenresistenz-assoziertem protein
WO2002002809A3 (en) Diagnosis of behavioural disorders, neurological disorders and cancer
DE69934227D1 (de) Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
WO1998054313A3 (en) Dna methyltransferase genomic sequences and antisense oligonucleotides
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
WO2000029623A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
DK1175489T3 (da) Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider
EP1264894A4 (de) REAKTIONSSYSTEME ZUR REGENERATION VON ATP UND METHODE ZUR PRüFUNG VON ADENIN NUKLEOTIDEN, METHODE ZUR DETEKTION VON RNA UND METHODE ZUR AMPLIFIKATION VON ATP UNTER VERWENDUNG DESSELBEN
ATE465261T1 (de) Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
WO1998032846A3 (en) Enzymatic nucleic acid treatment of diseases or conditions related to levels of c-fos
WO2001048245A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
EP1322658A4 (de) Oligonukleotidmodulation der her-1-expression
DE69430740T2 (de) ANTISENSE OLIGONNUKLEOTIDE DIE MIT DER mRNA CAP AKTIVITÄT INTERFERIEREN UND DIE TRANSLATION INHIBIEREN
WO2002091926A3 (en) Inhibitors of dna methyltransferase isoforms
AU3956100A (en) Rna polymerase i transcription factor tif-ia
IL149640A0 (en) Antisense oligonucleotides

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee